Table 2.
The distribution of adjuvant chemotherapy, radiotherapy and endocrine therapy among the early-stage breast cancer patients included into the analysis
| Discovery cohort n (%) | Validation cohort n (%) | P-valuea | |
|---|---|---|---|
| Number of patients | 413 | 108 | |
| Adjuvant chemotherapy | 0.452 | ||
| Anthracycline-based + taxane | 93 (22.5%) | 24 (22.2%) | |
| Anthracycline-based | 82 (19.9%) | 30 (27.8%) | |
| Other chemotherapy | 18 (4.4%) | 4 (3.7%) | |
| Trastuzumab + chemotherapy | 51 (12.3%) | 8 (7.4%) | |
| No adjuvant chemotherapy | 167 (40.4%) | 42 (38.9%) | |
| Missing | 2 (0.5%) | 0 | |
| Adjuvant radiotherapy | 0.425 | ||
| Yes | 361 (87.4%) | 91 (84.3%) | |
| No | 52 (12.6%) | 17 (15.7%) | |
| The first prescribed adjuvant endocrine therapy | 0.004 | ||
| Tamoxifen | 109 (26.4%) | 39 (3.6%) | |
| Aromatase inhibitor | 145 (35.1%) | 45 (41.7%) | |
| Goserelin and tamoxifen | 1 (0.2%) | 1 (0.9%) | |
| Other endocrine therapy | 2 (0.5%) | 1 (0.1%) | |
| No endocrine therapy | 154 (37.3%) | 21 (19.4%) | |
| Missing | 2 (0.5%) | 1 (0.9%) |
aFisher´s exact test